Abstracts tagged "Biomarkers"

Abstract Number: 0723 • ACR Convergence 2025
Neutrophil and Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis: Phenotype-based Characterization and Response to Mepolizumab
Michele Moretti¹, Francesco Ferro², Francesco Pisani³, Elisa Ferrigno³, Gaetano La Rocca⁴, Federica Di Cianni⁵, Rosaria Talarico⁶, Marta Mosca⁷, Chiara Baldini⁷ and Ilaria Puxeddu³, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ⁵Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶Azienda Ospedaliero Universitaria Pisana, Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Pisa, Italy
Background/Purpose: EGPA variably presents eosinophil (EOS)-related features and vasculitic manifestations. Recent introduction of mepolizumab (MEP) has revolutionized the treatment of EOS manifestations of EGPA. However,…
Abstract Number: 0307 • ACR Convergence 2025
Cytokine Profiling of Molecular Endotypes of Knee Osteoarthritis: Insights from the IMI-APPROACH cohort
Monica T. Hannani¹, Jaume Bacardit², Jonathan Larkin³, Virpi Glumoff³, Morten A. Karsdal¹, Anne-Christine Bay-Jensen¹, Ali Mobasheri³ and Christian Thudium⁴, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Newcastle University, Newcastle upon Tyne, United Kingdom, ³University of Oulu, Oulu, Finland, ⁴Nordic Bioscience, Herlev, Denmark
Background/Purpose: There has been a surging interest in characterizing subpopulations of osteoarthritis (OA) to facilitate recruitment of the right subgroups for drug development. The APPROACH…
Abstract Number: 0042 • ACR Convergence 2025
Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis
Steven Dang¹, Xianwei Li², Sydney Thib³, Darshini Ganatra⁴, liqun Diao⁵, Igor Jurisica⁶, Vinod Chandran⁷ and Lihi Eder⁸, ¹Institute of Medical Science, University of Toronto, Toronto, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada, ³Women’s College Research Institute, Toronto, Canada, ⁴Gladman Krembil Psoriatic Arthritis Research Program; Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Canada, ⁵Department of Statistics and Actuarial Science, University of Waterloo, Toronto, Canada, ⁶University Health Network, Toronto, Canada, ⁷Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ⁸University of Toronto, Toronto, ON, Canada
Background/Purpose: Our recent study characterized immune endotypes in psoriatic arthritis (PsA) patients using mass cytometry of peripheral blood1. We identified an endotype characterized by high…
Abstract Number: 2700 • ACR Convergence 2025
Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome
Chloe Palmer¹, Gustaf Wigerblad², Tom Hill³, Benjamin Turturice¹, Urvashi Kaundal¹, Paul Schaughency³, Bhavisha Patel⁴, Emma Groarke⁵, Neal Young⁵, Stefania Dell'orso¹ and Peter Grayson⁶, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Health, Stockholm, Sweden, ³NIAID, NIH, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, ⁵National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe adult-onset inflammatory disease caused by somatic mutations of the ubiquitin-like modifier activating enzyme…
Abstract Number: 2502 • ACR Convergence 2025
Deciphering Systemic Sclerosis Phenotypes: A Novel Approach Using Clustering Algorithms and Proteomic Insights. Results from the PRECISESADS Study
Santiago Dans Caballero¹, Rafaela Ortega-Castro², Chary López pedrera³, Alejandro Escudero⁴, Beatriz Vellón-García⁵, Carlos Pérez Sánchez⁶ and Clementina López Medina⁷, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain, ⁵Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁷Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Systemic sclerosis (SSc) is a clinically and biologically heterogeneous autoimmune disease characterized by multiorgan involvement, substantial morbidity, and high mortality. Traditional classification systems (based…
Abstract Number: 2247 • ACR Convergence 2025
A Pilot Study to identify novel autoantibody biomarkers in Rheumatoid Arthritis (RA) patients using Immunome Protein Array
Margaret Ma¹, Peter Cheung¹, ee tzun koh², janique peyper³, bermet abylova³ and Khai Pang Leong², ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³Standard BioTools, Singapore, Singapore
Background/Purpose: RA is a heterogenous condition with variable outcomes. The identification of novel autoantibodies and autoantibody signatures could help us identify potential diagnostic and prognostic…
Abstract Number: 2012 • ACR Convergence 2025
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
ullrich schwertschlag¹, yan yang², Jingfei li³, Roy Wu⁴, adam jin² and William Shi⁵, ¹Atom Therapeutics, PALO ALTO, CA, ²Atom Therapeutics, Suzhou, China (People's Republic), ³Atom Therapeutics, Suzhou, Jiangsu, China (People's Republic), ⁴Atom Bioscience, San Francisco, CA, ⁵Atom Therapeutics, Newark, CA
Background/Purpose: ABP-671 is a novel, selective and potent URAT1 inhibitor in development for the treatment of elevated serum uric acid (sUA) levels and gout.Methods: Subjects…
Abstract Number: 1778 • ACR Convergence 2025
Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers
Verónica Pulito Cueto¹, Joao Carlos Batista-Liz¹, Rebeca Nieto-Nieto², Clara Vaquera-Illescas², Diego San Emeterio-Villar², Daniel Vicente-Mínguez², María Sebastián Mora-Gil², Belén Atienza-mateo³, Ana Serrano-Combarro⁴, David Iturbe-Fernández⁵, Victor M. Mora-Cuesta⁵, Carolina Aguirre-Portilla⁴, Jose M Cifrián⁵, Ricardo Blanco⁴ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ⁴Immunopathology Group, IDIVAL and Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the leading cause of mortality in patients with connective tissue diseases (CTDs) [1]. The onset of CTD-ILD…
Abstract Number: 1668 • ACR Convergence 2025
A clinically validated assay for rapid determination of type I and type II interferon activity in pediatric inflammatory diseases
Evan Hsu¹, Courtney Leson², Amrita Basu³, Michael Lam⁴, Jian Yue⁴, Casey Rimland⁵, Rachel Weng⁴, Lauren Henderson⁶, Joyce Chang², Mary Beth Son⁴, Fatma Dedeoglu⁴, roshini Abraham³ and Pui Lee¹, ¹Boston Children's Hospital, Newton, MA, ²Boston Children's Hospital, Boston, ³Nationwide Children's Hospital, Columbus, OH, ⁴Boston Children's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, ⁶Boston Children's Hospital, Watertown, MA
Background/Purpose: Type I interferons (IFN-I) and type II interferon (IFN-g) are essential to host defense but dysregulated production of these cytokines is increasingly recognized in…
Abstract Number: 1380 • ACR Convergence 2025
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Beatrice Dei¹, Stefano Donati¹, Gaetano La Rocca², Giovanni Fulvio¹, Federico Fattorini¹, Antonello Sulis¹, Michele Moretti¹, Elena Elefante¹, Francesco Ferro³, Giulia Ricci⁴, Marta Mosca⁵ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Neurology Unit, University of Pisa, Pisa, Toscana, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
Abstract Number: 1187 • ACR Convergence 2025
Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
Tulaton Sodsri¹, Nattanicha Chaisrimaneepan², Ben Thiravetyan³, Rabhas Boonyawairote⁴, Nopavit Mohpichai⁵, Nutchapon Xanthavanij⁶, Natnicha Jakramonpreeya⁷, Pintip Ngamjanyaporn⁸ and Tananchai Petnak⁸, ¹Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand, ²Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, ⁴University of Illinois at Chicago, Chicago, ⁵Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁶Mount Auburn Hospital, Harvard Medical School, Cambridge, ⁷Chakri Naruebodindra Medical Institute, Bangkok, Thailand, ⁸Ramathibodi Hospital, Bangkok, Thailand
Background/Purpose: The associations between various myositis-specific antibodies (MSAs), rapidly progressive interstitial lung disease (RP-ILD), and mortality in antisynthetase syndrome (ASS) have been previously reported in…
Abstract Number: 0636 • ACR Convergence 2025
AA Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways
Sepehr Taghavi¹, Ines Silva², Jacob Vasquez³, Vasileios Kyttaris⁴, Tyler O'Malley⁵ and Mike Nerenberg⁶, ¹Exagen Inc, Escondido, CA, ²Exagen, Carlsbad, CA, ³Exagen, Inc., Vista, CA, ⁴Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ⁵Exagen, Vista, CA, ⁶Exagen, DEL MAR, CA
Background/Purpose: Lupus nephritis (LN) and diabetic kidney disease (DKD) are leading causes of chronic kidney disease (CKD) that differ by age, sex, and underlying mechanisms.…
Abstract Number: 0844 • ACR Convergence 2025
Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis
Kimberly Lakin¹, John Spivack¹, Jessica Gordon¹, Dana Orange² and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: As treatment options for diffuse cutaneous systemic sclerosis (dcSSc) expand, the need for data-driven, efficient approaches to therapeutic switching is becoming more urgent. Additionally,…
Abstract Number: 0531 • ACR Convergence 2025
Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
Anthony Marotta¹, Walter P. Maksymowych², Stephen Bleakley¹, Stephanie Wichuk³ and Norma Biln⁴, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: Novel biomarkers for axSpA are urgently needed to enable earlier diagnosis and improve patient outcomes. An assay for quantifying 14-3-3η autoantibodies (AAbs) has been…
Abstract Number: 0303 • ACR Convergence 2025
A Predictive Model for Liver Enzyme Elevations Based on Creatine Kinase in Idiopathic Inflammatory Myopathies
Shiri Keret¹, Tanya Chandra², Nantakarn Pongtarakulpanit², Kaushik Sreerama Reddy², Jesse Wilkerson³, Siamak Moghadam-Kia⁴, Dana Ascherman⁵, Chester V. Oddis⁵ and Rohit Aggarwal⁶, ¹Bnai Zion Medical Center, Atlit, Israel, ²University of Pittsburgh Medical Center, Pittsburgh, ³DLH, Bethesda, MD, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by elevated muscle enzymes, including creatine kinase (CK), aldolase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase…

« Previous Page
1
…
3
4
5
6
7
…
109
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].